SCHEMBL1010705

SCHEMBL1010705

CC(C)(C)OC(=O)N1CCC(=Cc2ccc(Cl)c(Oc3ccc(C(F)(F)F)cn3)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 11/20 0.50
CYP3A4 P08684 4/20 0.50
CYP2D6 P10635 4/20 0.50
GABRA1 P14867 1/20 0.50
ADRA2C P18825 1/20 0.50
CNR1 P21554 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
CNR2 P34972 1/20 0.50
HTR2B P41595 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
LIPE Q05469 4/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BCHE P06276 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011759 0.90 CYP3A4 (0.52) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1012025 0.88 FAAH (0.51) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1010150 0.84 FAAH (0.69) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1011894 0.82 CYP3A4 (0.56) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1014193 0.82 FAAH (0.55) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1012251 0.81 FAAH (0.54) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1011456 0.80 CYP3A4 (0.76) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL2543044 0.79 CYP3A4 (0.55) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL1009405 0.79 FAAH (0.52) FAAHCYP3A4CYP2D6GABRA1ADRA2C
SCHEMBL11949150 0.79 ESR2 (0.39) CYP3A4KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC FAAH 1/4885CYP3A4 303/4885CYP2D6 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.